British Columbia Hepatitis Testers Cohort: HCV Reinfection Rate ~ 2/100 PY Following SVR With DAA Treatment Among Persons Who Inject Drugs

November 8-12, 2019; Boston, Massachusetts
HCV reinfection rates in British Columbia were relatively low following SVR with DAA treatment but were higher among persons who inject drugs vs the overall cohort.
Format: Microsoft PowerPoint (.ppt)
File Size: 211 KB
Released: November 20, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AbbVie
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.

Related Content

CCO downloadable slides from Dr. Tatyana Kushner providing insights on updated guidance for HCV screening and management in women of childbearing age

Tatyana Kushner, MD, MSCE Released: January 8, 2021

CCO module by Dr. Mark Sulkowski on optimal HCV management in PWID, children, liver transplant recipients and patients with renal disease or HIV

Stefan Zeuzem, MD
Program Director
Mark S. Sulkowski, MD
Released: December 28, 2020

CCO commentary from Catherine Chappell, MD, MSc, on the challenges of HCV management in women of childbearing age, including during pregnancy.

person default Catherine Chappell, MD, MSc Released: December 22, 2020

CCO commentary from Tatyana Kushner, MD, MSCE, on the important role of universal HCV testing for pregnant women

Tatyana Kushner, MD, MSCE Released: December 14, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue